David M. Vigushin - Concepedia

Author

David M. Vigushin

Also Known As

D M Vigushin, D Vigushin, D. M. Vigushin, D. Vigushin, D.M. VIGUSHIN, D.M. Vigushin, David M Vigushin, David M. Vigushin, David Vigushin

Publications

4.8K

Citations

H-Index

Concepts

All Affiliations

Hammersmith Hospital Imperial College London Charing Cross Hospital Cancer Research UK Institute of Cancer Research

About

David M. Vigushin is an author at Hammersmith Hospital specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	19	2.3K
2	Natural Sciences	4	4	192
3	Health Sciences	2	2	366
4	Public Health	2	2	23
5	Engineering	1	1	275

David M. Vigushin

Publications

4.3K

Citations

H-Index

Page 1

	Year	Citations
Human lysozyme gene mutations cause hereditary systemic amyloidosis Mark B. Pepys, Philip N. Hawkins, David R. Booth, Nature Alzheimer's DiseaseMendelian DisorderGenetic DisorderGeneticsPathology	1993	655
Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. David M. Vigushin, Mark B. Pepys, Philip N. Hawkins Journal of Clinical Investigation ImmunologyPathologyScintigraphic StudiesOxidative StressInflammation	1993	635
Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. David M. Vigushin, Simak Ali, Paul Pace, PubMed	2001	442
Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography Laura Kenny, R. Charles Coombes, David M. Vigushin, European Journal of Nuclear Medicine and Molecular Imaging Positron Emission TomographyEarly ChangesEngineeringHealth SciencesMedical Imaging	2007	275
Phase I and pharmacokinetic study of d -limonene in patients with advanced cancer David M. Vigushin, Grace K. Poon, Alan V. Boddy, Cancer Chemotherapy and Pharmacology Advanced CancerMedicinePharmacologyPharmacokinetic StudyD -Limonene	1998	240
Phase I Study of STX 64 (667 Coumate) in Breast Cancer Patients: The First Study of a Steroid Sulfatase Inhibitor Susannah Stanway, Atul Purohit, L. W. Lawrence Woo, Clinical Cancer Research	2006	238
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial Andreas Polychronis, H D Sinnett, Dimitri Hadjiminas, The Lancet Oncology Breast OncologyMedicineGynecologyBreast CancerCancer Treatment	2005	194
Quantification of Cellular Proliferation in Tumor and Normal Tissues of Patients with Breast Cancer by [18F]Fluorothymidine-Positron Emission Tomography Imaging: Evaluation of Analytical Methods Laura Kenny, David M. Vigushin, Adil Al‐Nahhas, Cancer Research	2005	178
Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. Anne K. Soutar, Philip N. Hawkins, David M. Vigushin, Proceedings of the National Academy of Sciences Alzheimer's DiseaseBiochemistryAutosomal Dominant AmyloidosisMedicineGenetics	1992	143
Histone Deacetylase Inhibitor Trichostatin A Represses Estrogen Receptor α-Dependent Transcription and Promotes Proteasomal Degradation of Cyclin D1 in Human Breast Carcinoma Cell Lines John P. Alao, Eric W.‐F. Lam, Simak Ali, Clinical Cancer Research	2004	113

Page 1